Sarah Hill X OhmBody

I’m excited to announce a new research partnership with OhmBody, a company developing noninvasive vagus nerve stimulation technology designed to support women’s health.

Together, we are collaborating on research examining how vagus nerve stimulation may influence symptoms associated with PMDD (premenstrual dysphoric disorder) and perimenopause—two life stages where disruptions in mood, stress regulation, and physiological resilience are common and often under-treated.

This partnership reflects a shared commitment to studying women’s bodies as they actually function, rather than forcing female biology into male-default models of health.

The vagus nerve plays a central role in regulating the autonomic nervous system, inflammation, mood, and stress responses—all systems that are deeply implicated in cyclical mood symptoms and the hormonal transitions of perimenopause.
Importantly, vagus nerve stimulation is already supported by a growing body of research. Prior studies have shown that this approach can:

• Reduce heavy menstrual bleeding
• Improve stress regulation and autonomic balance
• Support mood and emotional regulation in treatment-resistant conditions

Our collaboration builds on this existing foundation by asking more precise, female-specific questions:

• How does vagus nerve stimulation interact with hormonal fluctuations?
• Can it improve resilience across the menstrual cycle and during perimenopause?
• And how might it support women whose symptoms have been dismissed or inadequately treated?